A randomised, double-blind, parallel-group, placebo-controlled and active-referenced study evaluating the efficacy and safety of three fixed dose regimens of Lu AA34893 in the treatment of Major Depressive Disorder.

H. Lundbeck A/S0 个研究点目标入组 600 人开始时间: 2008年6月27日最近更新: 2022年4月4日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: H. Lundbeck A/S
入组人数: 600

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•A patient, who meets all the following criteria, both at the Screening Visit and at the Baseline Visit, is eligible for inclusion in this study:
•1. The patient is able to read and understand the Subject Information Sheet.
•2. The patient has signed the Informed Consent Form.
•3. The patient suffers from a MDE as the principal diagnosis according to DSM-IV-TR
•(classification code 296.xx) as assessed by the MINI.
•4. The reported duration of the current Major Depressive Episode is at least 3 months.
•5. The patient has a MADRS total score =26.
•6. The patient is a man or woman, aged between 18 and 75 years (extremes included).
•7. The patient is an in-patient in a psychiatric hospital or an out-patient at a psychiatric setting.
•8. The patient, if female, must:
•- agree not to try to become pregnant during the study, AND
•- use adequate contraception (adequate contraception is defined as oral/systemic
•contraception, intrauterine device, diaphragm in combination with spermicide, or
•condom for male partner in combination with spermicide), OR
•- have had her last natural menstruation at least 24 months prior to baseline, OR
•- have been surgically sterilised prior to baseline, OR
•- have had a hysterectomy prior to baseline, OR
•- not be sexually active
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•A patient who meets one or more of the following criteria at the Screening Visit and/or at the Baseline Visit, is not eligible for inclusion in this study:
•1. The patient has one or more of the following conditions:
•- Any current psychiatric disorder established as the principal diagnosis other than
•MDD as defined in the DSM-IV-TR (assessed by the MINI).
•- Current or past history of: manic or hypomanic episode, schizophrenia or any other
•psychotic disorder, including major depression with psychotic features, mental
•retardation, organic mental disorders, or mental disorders due to a general medical
•condition as defined in the DSM-IV-TR.
•- Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR.
•- Presence or history of a clinically significant neurological disorder (including
•epilepsy, stroke).
•- Neurodegenerative disorder (Alzheimer’s disease, Parkinson’s disease, multiple
•sclerosis, Huntington’s disease, etc.).
•- Any axis II disorder that might compromise the study.
•2. The patient, in the opinion of the investigator, has a significant risk of suicide, or has a score =5 on item 10 (suicidal thought) of the MADRS or has made a suicide attempt in the previous 6 months.
•3. The current depressive symptoms of the patient are considered by the investigator to have been resistant to two or more adequate antidepressant treatments of at least 6 weeks duration.
•4. The patient has used or uses disallowed recent or concomitant medication (specified in Appendix II, Recent and Concomitant Medication), or it is anticipated that the patient will require treatment with at least one of the disallowed concomitant medications during the study.
•5. The patient has received electroconvulsive therapy within 6 months prior to screening.
•6. The patient is currently receiving formal cognitive or behavioural therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
•7. The patient has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, skin and subcutaneous tissue disorders or metabolic disturbance.
•8. The patient has a chronic liver disease.
•9. The patient has clinically significant abnormal vital signs.
•10. The patient has received venlafaxine as treatment for the current depressive episode.
•11. The patient has a history of lack of response to previous adequate treatment with venlafaxine (including current episode).
•12. The patient has a history of severe drug allergy or hypersensitivity, or known
•hypersentivity to venlafaxine.
•13. The patient has an identified very high risk of a serious cardiac ventricular arrhythmia (e.g. those with a significant left ventricular dysfunction, NYHA Class III/IV), uncontrolled hypertension or recent history of myocardial infarction.
•14. The patient has one or more laboratory values outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant.
•15. The patient has TSH value outside the normal range at Screening Visit.
•16. The patient has a clinically significant abnormal ECG.
•17. The patient has a QTc interval on the ECG above 450 ms in accordance to the Fredericia method (QTc=QT/RR0.33), a history of long QT syndrome and/or a history of hypokalaemia.
•18. The patient has a disease or takes medication that,

研究者

发起方

H. Lundbeck A/S

相似试验

进行中（未招募）

不适用

A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of three dosages of Lu AA21004, in acute treatment of Major Depressive Disorder. - Not applicableMedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSMajor Depressive Disorder

EUCTR2007-001870-95-BGH. Lundbeck A/S660

进行中（未招募）

不适用

A randomised, double-blind, parallel-group, placebo-controlled and active-referenced study evaluating the efficacy and safety of three fixed dose regimens of Lu AA34893 in the treatment of Major Depressive Disorder.MedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSMajor Depressive Disorder

EUCTR2007-007025-51-EEH. Lundbeck A/S600

进行中（未招募）

不适用

A randomised, double-blind, parallel-group, placebo controlled study ofesomeprazole i.v. (bolus infusion of 80 mg followed by a continuous infusionof 8 mg per hour) administered for 72 hours to assess prevention ofrebleeding in subjects that have undergone successful primary endoscopichaemostasis of a bleeding peptic ulcer – the PUB study - NAGatrointestinal haemorrhages NEC. (Bleeding gastric or duodenal ulcer will be investigated).MedDRA classification code Level: HLGT = High Level Group Term. See below.MedDRA version: 8.0Level: HLGTClassification code 10017959

EUCTR2005-002441-39-ATAstraZeneca AB760

进行中（未招募）

不适用

EUCTR2007-007025-51-CZH. Lundbeck A/S600

进行中（未招募）

1 期

EUCTR2007-001870-95-FRH. Lundbeck A/S660